InsiderTrades

Form 4 for AMGN Amgen

Accepted 2022-04-29 00:00:00 ET · period of report 2022-04-27 · accession 0001127602-22-012758 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2022-04-29 2022-04-27 AMGN Bradway Robert A COB, CEO, Pres, Dir F - Tax $249.87 -2,547 610.8K -0.4% -$636.4K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-04-27 F D 2,547 $249.87 610,769 D — — (F1) These shares include the following RSUs granted under the Company's equity plans: 10,580 RSUs which vest in installments of 5,211 on 5/3/2022 and 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; and 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 2,174 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.